The $109 Billion Fund Behind Novo Says US Renewables Are Now 'Much More Attractive'
3 Articles
3 Articles
The $109 Billion Fund Behind Novo Says US Renewables Are Now 'Much More Attractive'
After curbing allocations earlier this year, the $109 billion investment fund behind Novo Nordisk A/S is back in full swing and looking for opportunities in a US market that’s now attractively priced, according to its chief executive.
Novo Nordisk CEO sees ‘long runway’ for weight-loss drugs as obesity grips America
The boom in weight-loss drugs may have transformed the obesity market, but Novo Nordisk’s CEO says the industry is still only scratching the surface with tens of millions of Americans potentially eligible for treatment.Novo Nordisk President and CEO Mike Doustdar joined FOX Business’ Cheryl Casone on "Mornings with Maria" to discuss the adoption of GLP-1 drugs, their potential economic impact and the company’s outlook for medicines, including We…
According to Eli Lilly itself, their new campaign on Danish soil is not an attempt to sell weight loss medication.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
